INOVIQ Past Earnings Performance
Past criteria checks 0/6
INOVIQ's earnings have been declining at an average annual rate of -33.8%, while the Healthcare industry saw earnings growing at 1.5% annually. Revenues have been growing at an average rate of 31.9% per year.
Key information
-33.8%
Earnings growth rate
-18.2%
EPS growth rate
| Healthcare Industry Growth | 2.4% |
| Revenue growth rate | 31.9% |
| Return on equity | -38.9% |
| Net Margin | -410.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ)
Mar 01
We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package
Nov 22Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth
Jun 21Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth
Feb 16INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans
Sep 28We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely
Jun 08We're Keeping An Eye On INOVIQ's (ASX:IIQ) Cash Burn Rate
Jan 28Are Insiders Selling BARD1 Life Sciences Limited (ASX:BD1) Stock?
Mar 02Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1)
Mar 02BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans
Dec 28Revenue & Expenses BreakdownBeta
How INOVIQ makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -7 | 6 | -1 |
| 30 Sep 23 | 2 | -8 | 7 | 0 |
| 30 Jun 23 | 2 | -9 | 8 | 0 |
| 31 Mar 23 | 2 | -15 | 8 | 0 |
| 31 Dec 22 | 2 | -21 | 8 | 1 |
| 30 Sep 22 | 2 | -20 | 7 | 0 |
| 30 Jun 22 | 2 | -18 | 6 | 0 |
| 31 Mar 22 | 2 | -14 | 6 | 0 |
| 31 Dec 21 | 1 | -11 | 5 | -1 |
| 30 Sep 21 | 1 | -11 | 5 | 0 |
| 30 Jun 21 | 1 | -11 | 4 | 0 |
| 31 Mar 21 | 1 | -8 | 4 | 1 |
| 31 Dec 20 | 1 | -5 | 3 | 1 |
| 30 Sep 20 | 1 | -4 | 3 | 1 |
| 30 Jun 20 | 1 | -3 | 2 | 0 |
| 31 Mar 20 | 1 | -3 | 2 | 0 |
| 31 Dec 19 | 0 | -2 | 2 | 0 |
| 30 Sep 19 | 1 | -2 | 2 | 0 |
| 30 Jun 19 | 1 | -2 | 2 | 0 |
| 31 Mar 19 | 0 | -2 | 1 | 0 |
| 31 Dec 18 | 0 | -2 | 1 | 0 |
| 30 Sep 18 | 0 | -2 | 1 | 0 |
| 30 Jun 18 | 0 | -2 | 1 | 0 |
| 31 Mar 18 | 0 | -2 | 1 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
| 30 Sep 17 | 0 | -2 | 1 | 0 |
| 30 Jun 17 | 0 | -3 | 1 | 0 |
| 30 Jun 16 | 0 | -6 | 0 | 0 |
| 31 Dec 15 | 0 | 0 | 0 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
Quality Earnings: IIQ is currently unprofitable.
Growing Profit Margin: IIQ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IIQ is unprofitable, and losses have increased over the past 5 years at a rate of 33.8% per year.
Accelerating Growth: Unable to compare IIQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IIQ is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-19.1%).
Return on Equity
High ROE: IIQ has a negative Return on Equity (-38.88%), as it is currently unprofitable.